Your browser doesn't support javascript.
Potential Association of Remdesivir and Hyperkalemia: A Disproportionality Analysis in USFDA Adverse Event Reporting System Database
Value in Health ; 26(6 Supplement):S172, 2023.
Artículo en Inglés | EMBASE | ID: covidwho-20234607
ABSTRACT

Background:

Signal detection is one of the most advanced and promising techniques in the world of pharmacovigilance. Remdesivir is approved for emergency use by the US Food and Drug Administration (FDA) for patients with coronavirus disease 2019 (COVID-19). Its benefit- risk ratio is still being explored because data in the field are rather scant. On the other hand hyperkalemia is a potentially life-threatening electrolyte disorder. Severe hyperkalemia can occur suddenly and can cause life-threatening heart rhythm changes (arrhythmia) that cause a heart attack. Even mild hyperkalemia can cause heart related problems over time if not treated. Objective(s) To evaluate the potential association of Remdesivir with risk of Hyperkalemia by analyzing the spontaneous reports through disproportionality analysis. Method(s) Data were obtained from the public release of data in FAERS. Case/non-case method was adopted for the analysis of association between Remdesivir use and Hyperkalemia. The data-mining algorithm used for the analysis were Reporting Odds Ratio(ROR) and Proportional Reporting Ratio (PRR). A value of ROR-1.96SE>, PRR>=2 were considered as positive signal. Result(s) A total of 7 DE's associated with Remdesivir use and hyperkalemia were reported. The mean age of the patients of Remdesivir associated events was found to be 75 years [95% CI]. The reports by gender were distributed with a male to female ratio of 31, though gender was not revealed in 3 reports. The data mining algorithms exhibited positive signal for hyperkalemia (PRR 2.349, ROR 2.354) upon analysis as those were well above the pre-set threshold. Three case reports were identified which strengthened these findings and highlighted the importance of laboratory parameters for the early detection of hyperkalemia Conclusion(s) The current study found a potential risk of hyperkalemia with the use of Remdesivir and there is an urgent need to thoroughly investigate the same and take the necessary action to avoid or minimize the risk.Copyright © 2023
Palabras clave

Texto completo: Disponible Colección: Bases de datos de organismos internacionales Base de datos: EMBASE Tipo de estudio: Estudio experimental / Estudio pronóstico / Revisiones Idioma: Inglés Revista: Value in Health Año: 2023 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos de organismos internacionales Base de datos: EMBASE Tipo de estudio: Estudio experimental / Estudio pronóstico / Revisiones Idioma: Inglés Revista: Value in Health Año: 2023 Tipo del documento: Artículo